We are pleased to share a recent interview with our CEO and Co-Founder, Lluna Gallego, conducted by Catalyze, an innovation consultancy that supports organisations in securing funding and translating scientific ideas into impactful projects.
Catalyze is an innovation consulting company focused on helping organisations bring new technologies to market and secure funding to support their development. With over 20 years of experience and a team of more than 100 experts, Catalyze combines scientific knowledge with business strategy to support clients across life sciences, sustainability, digitalisation and industrialisation.
Vector Bioscience collaborated with Catalyze during the preparation of our successful application to the EIC Transition programme (2022 call), through which we secured €2.5 million in funding for our GENERA project.
Catalyze supported us throughout the application process, helping to structure and position the proposal in line with EIC expectations. Their contribution included guidance on project scope, development of the business plan, and preparation for the interview stage. This support was instrumental in translating our scientific work into a clear and competitive proposal.
In this interview, Catalyze highlights Vector Bioscience’s work on developing a MOF-based drug-delivery platform, with a particular focus on RNA therapeutics.
The discussion centres on the GENERA project, which aims to address a key challenge in the field: the safe and effective delivery of short interfering RNA to target tissues. The project focuses initially on pancreatic cancer, a disease with limited treatment options and significant unmet clinical needs.
Lluna outlines how our platform uses the properties of MOFs, such as high porosity and tunable structure, to enable the encapsulation and controlled release of a wide range of therapeutic cargos, including RNA. She also discusses our approach to platform development, which integrates materials engineering with machine learning to improve predictability and support translation from research to application.
The GENERA project represents a key step in advancing our platform towards clinical and commercial development. Alongside our ongoing work in oncology, the platform is designed to be applicable across a range of therapeutic areas and modalities.
We thank Catalyze for their collaboration and for the opportunity to share our work through this interview.
Read the full interview here.